Status:
UNKNOWN
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Non Small Cell Lung Cancer
Stage III Non-small-cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidence...
Detailed Description
The frequency of EGFR mutations in patients with stage III inoperable adenocarcinoma or non-squamous cell carcinoma is 17-31%, which is relatively low. Compared to patients with EGFR wild type, the ef...
Eligibility Criteria
Inclusion
- histologically confirmed NSCLC with adenocarcinoma
- stage III (AJCC 7th edition)
- inoperable or refuse surgery
- EGFR-TKI mutation, specimen from tissue or blood
Exclusion
- the pathology was not adenocarcinoma
- stage I,II and IV
- anaplastic lymphoma kinase (ALK) rearrangement
- no follow-up data achievable
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT04304638
Start Date
March 1 2020
End Date
June 1 2020
Last Update
March 11 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.